ArticleMalaria journal2025
Deletion of target gene (histidine-rich protein 2/3) for Plasmodium falciparum rapid diagnostic tests in Amhara region, Ethiopia: a cross-sectional study.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Point of care performance of the improved BIOCREDIT Ag Pf/Pv (pLDH/pLDH) rapid diagnostic test: a cross-sectional study at a health center setting in Ethiopia.Malaria journal · 2026Article
- Resurgence of malaria in Ethiopia: a national landscape analysis of systemic and operational gaps.Malaria journal · 2026Article
- Local variability inMalariaWorld journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmodium falciparum histidine-rich protein 2 (pfhrp2)-based rapid diagnostic tests (RDTs) have been instrumental in enhancing malaria surveillance and case management, especially in Africa where P. falciparum predominates. However, the emergence of pfhrp2/3 gene deletions poses a serious threat to their effectiveness. Therefore, regular monitoring of pfhrp2/3 deletion status at both local and national levels is essential to inform policy decisions on appropriate diagnostic strategies.
methodsA health facility-based cross-sectional study was conducted from January 2021 to 2022 across 28 health facilities in three survey domains (Gondar, Gojjam, and East Amhara) within the Amhara region of Ethiopia. The study included 1232 microscopy-confirmed P. falciparum patients. Participants were recruited through convenient sampling based on informed consent. Socio-demographic and clinical data were collected using a structured questionnaire. Capillary blood samples were obtained and tested for Plasmodium infection using pfhrp2-based RDTs, microscopy, and polymerase chain reaction (PCR). PCR analysis specifically targeted the pfhrp2 and pfhrp3 genes to detect deletions. Descriptive statistics were performed using SPSS version 20.0 to summarize participant characteristics and calculate the prevalence of gene deletions.
resultsAmong 1232 microscopy-confirmed P. falciparum-positive samples, 123 were suspected of pfhrp2/3 gene deletion (i.e., microscopy positive but RDT negative). These 123 discordant samples and 87 samples with concordant RDT and microscopy-positive results (total 210) were recruited for the pfhrp2/3 gene deletion study using PCR. An additional 17 concordant and 14 discordant samples (a total of 31) were excluded due to insufficient DNA amplification. As a result, pfhrp2/3 gene deletion analysis was conducted on 179 samples. Of these, 158 (88.3%) samples had either one or both of the pfhrp2 and pfhrp3 gene deletions. Ninety-two (51.4%), 4 (2.2%) and 62 (34.6%) samples were with dual pfhrp2/3, Pfhrp2 and pfhrp3 gene deletions, respectively. Among 109 false-negative pfhrp2/3 RDT results, 102 (93.6%) were due to pfhrp2/3 gene deletions. P. falciparum with pfhrp2 and pfhrp3 or dual gene deletion was found in all survey domains.
conclusionsThe regional prevalence of pfhrp2/3 gene deletion is above the threshold (5%) recommended by the World Health Organization. Plasmodium falciparum strains with pfhrp2/3 gene deletion are distributed throughout the Amhara region. Continued use of the newly introduced LDH-based Biocredit RDTs is recommended in Ethiopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.